<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="discussion"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6008311</article-id><article-id pub-id-type="doi">10.3389/fimmu.2018.01335</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Opinion</subject></subj-group></subj-group></article-categories><title-group><article-title>Myocarditis: An Interleukin-1-Mediated Disease?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>De Luca</surname><given-names>Giacomo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="fn001">*</xref><uri xlink:type="simple" xlink:href="https://frontiersin.org/people/u/526934"/></contrib><contrib contrib-type="author"><name><surname>Cavalli</surname><given-names>Giulio</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Campochiaro</surname><given-names>Corrado</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="https://frontiersin.org/people/u/571547"/></contrib><contrib contrib-type="author"><name><surname>Tresoldi</surname><given-names>Moreno</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="https://frontiersin.org/people/u/571542"/></contrib><contrib contrib-type="author"><name><surname>Dagna</surname><given-names>Lorenzo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="https://frontiersin.org/people/u/164656"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University</institution>, <addr-line>Milan</addr-line>, <country>Italy</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Medicine, Radboud University Medical Center</institution>, <addr-line>Nijmegen</addr-line>, <country>Netherlands</country></aff><aff id="aff3"><sup>3</sup><institution>Unit of General Medicine and Advanced Care, IRCCS San Raffaele Hospital and Scientific Institute</institution>, <addr-line>Milan</addr-line>, <country>Italy</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Carlo Selmi, Universit&#224; degli Studi di Milano, Italy</p></fn><fn fn-type="edited-by"><p>Reviewed by: Charles Dinarello, University of Colorado Denver, United States</p></fn><corresp id="fn001">*Correspondence: Giacomo De Luca, <email>deluca.giacomo@hsr.it</email></corresp><fn fn-type="other" id="fn002"><p>Specialty section: This article was submitted to Cytokines and Soluble Mediators in Immunity, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>13</day><month>6</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>9</volume><elocation-id>1335</elocation-id><history><date date-type="received"><day>19</day><month>2</month><year>2018</year></date><date date-type="accepted"><day>29</day><month>5</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#169; 2018 De Luca, Cavalli, Campochiaro, Tresoldi and Dagna.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>De Luca, Cavalli, Campochiaro, Tresoldi and Dagna</copyright-holder><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><kwd-group><kwd>autoimmune myocarditis</kwd><kwd>interleukin-1</kwd><kwd>auto-inflammatory diseases</kwd><kwd>heart failure</kwd><kwd>anti-cytokine therapy</kwd></kwd-group><counts><fig-count count="1"/><table-count count="1"/><equation-count count="0"/><ref-count count="87"/><page-count count="8"/><word-count count="6122"/></counts></article-meta></front><body><sec sec-type="introduction" id="S1"><title>Introduction</title><p>Myocarditis is defined by WHO as an inflammatory disease affecting the myocardium, diagnosed by endomyocardial biopsy (EMB) using established histological, immunological, and immunohistochemical criteria; it may be idiopathic, infectious, or autoimmune (<xref rid="B1" ref-type="bibr">1</xref>&#8211;<xref rid="B4" ref-type="bibr">4</xref>). A wide variety of histological myocarditis patterns have been described according to the diverse etiologies and to the stage of the disease at the time of EMB ascertainment. Viral infections represent the most common cause in Europe and North America (<xref rid="B5" ref-type="bibr">5</xref>). Different viral genomes can be detected in the myocardium of patients with myocarditis and dilated cardiomyopathy (DCM) using molecular techniques (<xref rid="B6" ref-type="bibr">6</xref>&#8211;<xref rid="B14" ref-type="bibr">14</xref>). When no infectious agents are identified on EMB and other known causes are excluded, autoimmune myocarditis (AMy) is the presumed etiology (<xref rid="B15" ref-type="bibr">15</xref>). These so-called &#8220;autoimmune myocarditis&#8221; or &#8220;virus-negative myocarditis&#8221; may occur as a distinct disease with exclusive cardiac involvement, or in the context of systemic autoimmune or inflammatory disorders with extracardiac involvement (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B16" ref-type="bibr">16</xref>&#8211;<xref rid="B23" ref-type="bibr">23</xref>).</p><p>It is likely that several etiologic types of myocarditis confluence in a common immune-mediated pathogenic process leading to chronic inflammation and tissue damage. Irrespective of triggering agents, acute inflammation may progress to subacute and chronic stages and eventually result in tissue remodeling, fibrosis, contractile dysfunction, and finally DCM (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B24" ref-type="bibr">24</xref>&#8211;<xref rid="B29" ref-type="bibr">29</xref>). Besides contractile dysfunction, both early myocardial inflammation and late fibrotic changes play a critical role in the development of the arrhythmic burden, which makes myocarditis one of the leading causes of sudden death (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B27" ref-type="bibr">27</xref>&#8211;<xref rid="B31" ref-type="bibr">31</xref>). Clearly, treatment interventions effectively curbing the acute inflammatory process at an early stage can prevent late cardiac remodeling and improve patient&#8217;s outcome. Emerging evidence on the pathogenic mechanisms underlying cardiac inflammation is paving the way to novel, promising treatment strategies for myocarditis.</p></sec><sec id="S2"><title>Pathogenesis</title><p>Both autoimmune and innate inflammatory responses are involved in the pathogenesis of myocarditis and its sequelae; however, the specific contribution of either mechanism is not completely understood. As most of immune-mediated diseases, VNM is considered a multifactorial entity, with several immunologic mechanisms contributing to disease development and progression. Environmental triggers of myocardium damage lead to local inflammation and exposure of cryptic self-antigens: excessive innate and myocardium-specific immune responses ensue in genetically predisposed individuals (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B31" ref-type="bibr">31</xref>&#8211;<xref rid="B35" ref-type="bibr">35</xref>) and result in a self-sustained autoimmune or inflammatory cycle independent of the original triggering agent.</p><p>Traditionally, persistent autoimmune responses have been postulated to underlie the progression from myocarditis to DCM. Histologically, a lymphocytic infiltrate characterizes VNM, which is historically considered a CD4+ T cells mediated disease. Accordingly, transfer of CD4+ T-cells to severe combined immunodeficient mice induced the disease, while CD4+ T-cells depletion ameliorated experimental AMy (EAM). Additional immune cell-types characterizing cardiac inflammation in EAM include T-helper (Th)-1 and Th-17 cells, neutrophils, eosinophils, and monocytes/macrophages, representing a predominantly adaptive cellularity (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B34" ref-type="bibr">34</xref>). The role of innate immunity and auto-inflammatory mechanisms in the pathogenesis of myocarditis has traditionally received much less attention. Still, activation of the innate inflammatory response is required to prime and kick-off the adaptive immune response, and persistent inflammation is a critical cause of progressive tissue damage.</p></sec><sec id="S3"><title>The Auto-Inflammatory Hypothesis</title><p>As most tissues, the heart exhibits a stereotyped, highly conserved response to injuries, characterized by an intense inflammatory reaction. This response, eventually leading to myocardial inflammation and heart failure (HF), is mediated by the pro-inflammatory cytokine interleukin (IL)-1, as indicated by both clinical and experimental evidence. IL-1 is an apical pro-inflammatory cytokine: two distinct ligands (IL-1&#945; and IL-1&#946;) with high sequence homology exert their biological activity by binding the IL-1 type-I receptor (IL-1RI), which transduces pro-inflammatory signals leading to the synthesis and expression of hundreds of secondary inflammatory mediators (<xref rid="B35" ref-type="bibr">35</xref>). IL-1&#945; is produced by most epithelial cells as a fully active pro-inflammatory mediator, which is released upon cell death or stress in the case of tissue injury, thereby acting as an &#8220;alarmin.&#8221; Conversely, IL-1&#946; is mostly produced by monocyte-macrophages as an inactive precursor and requires cleavage by an intracellular molecular complex termed &#8220;inflammasome&#8221; in order to be secreted and exert potent pro-inflammatory effects (<xref rid="B35" ref-type="bibr">35</xref>&#8211;<xref rid="B38" ref-type="bibr">38</xref>). The same cells that produce IL-1&#945; or IL-1&#946; also synthesize various regulatory molecules to curb excessive inflammation (<xref rid="B35" ref-type="bibr">35</xref>&#8211;<xref rid="B38" ref-type="bibr">38</xref>), including the IL-1 receptor antagonist (IL-1Ra). Competitive binding of IL-1Ra to IL-1RI prevents IL-1 signaling and inhibits IL-1-mediated inflammation (<xref rid="B35" ref-type="bibr">35</xref>&#8211;<xref rid="B37" ref-type="bibr">37</xref>).</p><p>In myocarditis, IL-1&#945; is released from the dying myocardium together with debris and other inflammatory mediators, and these in turn activate the inflammasomes in nearby cells (<xref rid="B35" ref-type="bibr">35</xref>&#8211;<xref rid="B38" ref-type="bibr">38</xref>). Runaway IL-1-mediated inflammation ensues, progressively causing apoptosis of cardiomyocytes, loss of contractile tissue, fibrosis, cardiomyopathy, HF, and arrhythmic outburst (<xref rid="B39" ref-type="bibr">39</xref>) (Figure <xref ref-type="fig" rid="F1">1</xref>). Intracellular aggregates of apoptosis-associated speck-like protein containing CARD (ASC) and/or caspase-1, indicative of the formation of the inflammasome, can be observed in leukocytes, cardiomyocytes, fibroblasts, and endothelial-cells in EMB samples from patients with acute lymphocytic myocarditis or diagnosed as having myocarditis post-mortem (<xref rid="B39" ref-type="bibr">39</xref>). Of note, the number of inflammasome-containing leukocytes per-field correlated with HF severity: patients presenting with HF or with depressed left-ventricular ejection fraction (LVEF) at admission, as well as those who did not experience a significant 6-month LVEF recovery, exhibited a greater number of inflammasomes and inflammasome-containing leukocytes in heart specimens. These data indicate that a stereotyped tissue inflammatory response characterized by the formation of the inflammasome is present and associated with disease severity in acute myocarditis, thus substantiating the critical role of IL-1&#946; in both myocardial inflammation and systolic impairment.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Pathogenesis of myocarditis: the auto-inflammatory hypothesis. In myocarditis, a detrimental inflammatory response leads to cardiac damage, clinically manifested with contractile dysfunction. The pro-inflammatory cytokine interleukin (IL)-1 is of pivotal importance in the pathogenesis of myocardial inflammation. Inflammation of the heart results in myocardial injury. IL-1&#945; is released from the dying myocardiocytes, together with intracellular debris and inflammatory mediators; these in turn activate a molecular complex known as the &#8220;inflammasome,&#8221; resulting in processing and release of active IL-1&#946; by infiltrating inflammatory cells. Runaway cardiac inflammation ensues, leading to apoptosis of cardiomyocytes and loss of contractile tissue, cardiomyopathy, and heart failure. Given the dual efficacy against myocardial inflammation and contractile dysfunction, prompt pharmacologic inhibition of IL-1 can arrest the progression of uncontrolled inflammation, thus preventing extensive tissue damage and arrhythmic complications and restoring cardiac function.</p></caption><graphic xlink:href="fimmu-09-01335-g001"/></fig><p>The mechanisms linking IL-1 to impaired contractile function include inhibition of L-type calcium channels, uncoupling of the &#946;-adrenergic receptor (&#946;-AR) from the adenylyl-cyclase (<xref rid="B40" ref-type="bibr">40</xref>&#8211;<xref rid="B46" ref-type="bibr">46</xref>), and transcriptional and posttranslational changes in phospholamban and sarcoplasmic/endoplasmic reticulum calcium ATPase (<xref rid="B47" ref-type="bibr">47</xref>). IL-1 also increases nitric oxide (NO)-synthase expression leading to an increased NO activity, which mediates disruption of calcium and &#946;-AR signaling and mitochondrial dysfunction (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B48" ref-type="bibr">48</xref>&#8211;<xref rid="B50" ref-type="bibr">50</xref>).</p><p>Experimental observations in animal models also confirm the role of IL-1 in inflammatory HF: plasma from advanced HF patients induced a significant systolic and diastolic dysfunction and reduced contractile reserve in mice following a single injection, suggesting the presence of circulating cardiodepressant factors (<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B52" ref-type="bibr">52</xref>). Notably, administration of exogenous IL-1&#946; to mice had comparable effects, while pre-blocking of IL-1 prevented contractile dysfunction induced by HF serum, indicating that cardiodepressant effects are IL-1-mediated (<xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B53" ref-type="bibr">53</xref>). This role of IL-1 as a cardiodepressant factor is also described in sepsis (<xref rid="B54" ref-type="bibr">54</xref>).</p><p>Beyond a direct cardiodepressant activity, several lines of evidence point at a central role of IL-1 signaling in the induction and development of the immune processes associated with acute myocarditis. IL-1 expression is markedly upregulated in experimental models of AMy. Coxsackievirus-induced myocarditis in mice is also characterized by heart infiltration with inflammatory cells secreting IL-1 and TNF-&#945; (<xref rid="B55" ref-type="bibr">55</xref>). Persistently elevated IL-1&#946; expression was noted in the chronic stage of myocarditis in a mouse model of post-myocarditis DCM induced by the encephalomyocarditis-virus (<xref rid="B56" ref-type="bibr">56</xref>). Consistently, mice deficient for IL-1RI were protected from the development of AM (<xref rid="B57" ref-type="bibr">57</xref>), and IL-1Ra administration or expression had beneficial effects in experimental models of inflammatory cardiomyopathy: specifically, delivery of human IL-1Ra <italic>via</italic> plasmid vectors into the hearts of experimental animals with coxsackieviral or AMy decreased myocardial inflammation and reduced mortality (<xref rid="B58" ref-type="bibr">58</xref>&#8211;<xref rid="B61" ref-type="bibr">61</xref>). These findings were paralleled by observations in humans, as increased IL-1&#946; mRNA levels were found in EMBs from patients with viral myocarditis (<xref rid="B57" ref-type="bibr">57</xref>) and idiopathic DCM (<xref rid="B58" ref-type="bibr">58</xref>). Taken together, these evidences strongly suggest that IL-1 inhibition has the potentiality to simultaneously curb the heart inflammatory response and ameliorate myocardial contractility. Therapeutic agents specifically blocking IL-1 are available and used to treat a broad variety of autoimmune and inflammatory conditions (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B62" ref-type="bibr">62</xref>&#8211;<xref rid="B65" ref-type="bibr">65</xref>). Anakinra, the recombinant form of the naturally occurring IL-1Ra, blocks the activity of both IL-1&#945; and IL-1&#946; and is used to treat conditions characterized by IL-1-mediated inflammation. However, despite convincing evidence indicating a pivotal role of IL-1 in the pathogenesis of myocardial inflammation and myocarditis-related systolic dysfunction, the use of IL-1 blocking agents has been only anecdotally reported in this clinical condition.</p></sec><sec id="S4"><title>Current and Future Therapeutic Perspectives</title><p>Symptomatic treatment of HF and of arrhythmias is the mainstay of treatment in myocarditis (<xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B67" ref-type="bibr">67</xref>). So far, conventional immunosuppressive drugs (steroids, cyclosporine, and azathioprine), rather than targeted treatments, have been used in order to target the pro-inflammatory mediators of the disease. Single-center randomized trials (RTs) showed some benefits in chronic VNM/DCM (<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B69" ref-type="bibr">69</xref>), in giant-cell myocarditis (<xref rid="B70" ref-type="bibr">70</xref>) and in Amy (<xref rid="B71" ref-type="bibr">71</xref>). Recently, a single center controlled study demonstrated that combination of azathioprine and steroids can be moderately effective in the treatment of VNM refractory to standard of care (<xref rid="B69" ref-type="bibr">69</xref>). In the TIMIC-trial, patients with HF and biopsy-proven VNM were randomized to receive either prednisone 1&#8201;mg/kg per day for 4&#8201;weeks, followed by 0.33&#8201;mg/kg per day for 5-month plus azathioprine 2&#8201;mg/kg per day for 6&#8201;months, or placebo in addition to conventional therapy for HF. Primary outcome was the 6-month improvement in LVEF. Patients receiving prednisone plus azathioprine exhibited an improvement of LVEF and a decrease in LV volumes compared with baseline, while no patient in the placebo arm showed any improvement in LVEF. These results have been subsequently reproduced by other European observational studies (<xref rid="B72" ref-type="bibr">72</xref>, <xref rid="B73" ref-type="bibr">73</xref>). However, a proportion of patients with myocarditis treated with current immunosuppressive strategies showed a complete lack of response, an observation indicating that some critical mechanisms of disease pathogenesis and inflammatory tissue damage are not susceptible to conventional immunosuppression.</p></sec><sec id="S5"><title>Therapeutic IL-1 Blockade</title><p>Given the pivotal role of IL-1 in cardiac inflammation, it is expected that treatment with IL-1 blocking agents would curb inflammation and afford significant clinical benefits in patients with myocarditis. Clinical experience with specific IL-1 inhibition provides unambiguous confirmation to the role of IL-1 in human myocardial inflammation (Table <xref ref-type="table" rid="T1">1</xref>). Specifically, in different RTs of ST-elevation myocardial infarction (STEMI) and HF, treatment with anakinra was associated with improved cardiac contractility and function. Also of note, in all these trials, anakinra treatment was associated with marked reductions in serum inflammatory markers. In the recent, massive CANTOS trial of 10,061 patients with previous myocardial infarction and C-reactive protein (CRP)&#8201;&gt;&#8201;2&#8201;mg/l, selective blockade of IL-1&#946; with the monoclonal antibody canakinumab conferred protection against recurrent cardiovascular events (<xref rid="B74" ref-type="bibr">74</xref>); secondary analyses of results determined that more robust reductions in CRP after the first dose of canakinumab predicted greater clinical benefits, again confirming the role of IL-1 as driving force of cardiac and systemic inflammation (<xref rid="B74" ref-type="bibr">74</xref>&#8211;<xref rid="B80" ref-type="bibr">80</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Clinical experience with interleukin-1 inhibition in cardiac diseases.</p></caption><table-wrap-foot><p><italic>n, number; AOSD, adult-onset Still disease; CAD, coronary artery disease; CFR, coronary flow reserve; CRP, C-reactive protein serym levels; FMD, flow-mediated reserve; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEDVi, left ventricle end-diastolic volume index; LVEF, left ventricle ejection fraction; LVESVi, left ventricle end-systolic volume index; CMR, cardiac magnetic resonance; NSTEMI, non-ST-segment elevation myocardial infarction; ref, reference; STEMI, ST-segment elevation myocardial infarction; TTE, trans-thoracic echocardiography</italic>.</p><fn id="tfn1"><p><italic><sup>a</sup>VCU-ART and VCUART2 combined showed reduction in incidence of new HF with anakinra</italic>.</p></fn><fn id="tfn2"><p><italic><sup>b</sup>An exploratory analysis showed a marked reduction in the incidence of lung cancer, as well as lung cancer mortality and total cancer mortality. The treatment was associated with a higher incidence of fatal infection than was placebo</italic>.</p></fn><fn id="tfn3"><p><italic><sup>c</sup>Higher incidence of major adverse cardiac events at 12&#8201;months with anakinra</italic>.</p></fn><fn id="tfn4"><p><italic><sup>d</sup>Chronic: non randomized study: anakinra (150&#8201;mg, <italic>n</italic>&#8201;=&#8201;23) vs prednisolone (+5&#8201;mg over regular dose, <italic>n</italic>&#8201;=&#8201;19) for 30&#8201;days</italic>.</p></fn></table-wrap-foot></table-wrap><p>Besides dampening of inflammation, the beneficial effects of IL-1 blockade on cardiac function include amelioration of myocardial contractility. Early <italic>ex vivo</italic> studies with human atrial heart strips revealed that picomolar concentrations of IL-1 suppress contractile force (<xref rid="B81" ref-type="bibr">81</xref>). It was thus not unexpected that administration of anakinra to patients with refractory HF could improve exercise tolerance, while also dampening systemic pro-inflammatory mediators (<xref rid="B51" ref-type="bibr">51</xref>). IL-1 blockade with anakinra was also effective in the management of diastolic HF in a separate double-blind, placebo controlled trial (<xref rid="B82" ref-type="bibr">82</xref>). This direct beneficial effect of IL-1 inhibition on contractile function explains in part the near-instant clinical improvement observed in life-threatening cases of fulminant myocarditis, irrespective of the etiology (<xref rid="B83" ref-type="bibr">83</xref>&#8211;<xref rid="B85" ref-type="bibr">85</xref>). Similarly, in previous studies on patients with rheumatoid arthritis, anakinra promptly increased myocardial contractility within hours of a single dose administration (<xref rid="B86" ref-type="bibr">86</xref>, <xref rid="B87" ref-type="bibr">87</xref>).</p><p>Given this dual efficacy on tissue inflammation and contractile dysfunction, anakinra seems a particularly attractive option for patients with inflammatory HF due to myocarditis. A double blind, randomized, phase-IIb placebo-controlled clinical trial of anakinra in patients with acute myocarditis is ongoing (ARAMIS-trial, <uri xlink:type="simple" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT03018834?term=anakinra&amp;cond=myocarditis&amp;rank=1">https://www.clinicaltrials.gov/ct2/show/NCT03018834?term=anakinra&amp;cond=myocarditis&amp;rank=1</uri>). Experience is currently more limited with IL-1 blocking agents in the setting of chronic, VNM, and no clinical trials are presently evaluating this therapeutic option. However, VNM and DCM are histologically characterized by various degrees of inflammatory features, which precede and accompany fibrotic changes and drive both systolic impairment and arrhythmic complications. Prompt blockade of IL-1 can arrest the progression of uncontrolled inflammation, thus preventing fibrotic damage, curbing the arrhythmic burden, and restoring cardiac function. Also in light of a rapid onset of action and an excellent safety profile, IL-1 inhibition with anakinra represents a particularly suitable treatment option for conditions characterized by inflammatory HF, such as myocarditis with reduced LVEF.</p></sec><sec id="S6"><title>Conclusive Remarks</title><p>The inflammatory response in myocarditis spirals into a cycle of auto-inflammation, as intracellular contents released from dying myocardiocytes trigger the activation of the inflammasome and the uncontrolled release of IL-1 from neighboring cells. Selective and prompt pharmacologic inhibition of IL-1 dampens runaway inflammation and tissue damage, thus preventing arrhythmic complications and restoring cardiac function. Dual effectiveness against myocardial inflammation and contractile dysfunction renders IL-1 blockade a suitable therapeutic option for myocarditis.</p></sec><sec id="S7"><title>Author Contributions</title><p>GDL: conceived the hypothesis, contributed to the understanding of pathogenic mechanisms, clinical presentation and prognostic meaning of autoimmune myocarditis, and drafted the manuscript. GC: conceived the hypothesis, contributed to the understanding of biological effects of IL-1 and to the therapeutic usefulness of IL-1 in a broad spectrum of rheumatic diseases blockade, and critically revised the manuscript. CC: participated in previous studies focused on IL-1 blockade and myocarditis and critically revised the manuscript. MT: conceived the hypothesis and critically revised the manuscript. LD: conceived the hypothesis, critically revised the manuscript, and gave the approval of the final version.</p></sec><sec id="S8"><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>McKenna</surname><given-names>W</given-names></name><name><surname>Bristow</surname><given-names>M</given-names></name><name><surname>Maisch</surname><given-names>B</given-names></name><name><surname>Mautner</surname><given-names>B</given-names></name><name><surname>O&#8217;Connell</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Report of the 1995 World Health Organization/International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies</article-title>. <source>Circulation</source> (<year>1996</year>) <volume>93</volume>(<issue>5</issue>):<fpage>841</fpage>&#8211;<lpage>2</lpage>.<pub-id pub-id-type="doi">10.1161/01.CIR.93.5.841</pub-id><pub-id pub-id-type="pmid">8598070</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jefferies</surname><given-names>JL</given-names></name><name><surname>Towbin</surname><given-names>JA</given-names></name></person-group>. <article-title>Dilated cardiomyopathy</article-title>. <source>Lancet</source> (<year>2010</year>) <volume>375</volume>(<issue>9716</issue>):<fpage>752</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1016/S0140-6736(09)62023-7</pub-id><?supplied-pmid 20189027?><pub-id pub-id-type="pmid">20189027</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aretz</surname><given-names>HT</given-names></name><name><surname>Billingham</surname><given-names>ME</given-names></name><name><surname>Edwards</surname><given-names>WD</given-names></name><name><surname>Factor</surname><given-names>SM</given-names></name><name><surname>Fallon</surname><given-names>JT</given-names></name><name><surname>Fenoglio</surname><given-names>JJ</given-names><suffix>Jr</suffix></name><etal/></person-group>
<article-title>Myocarditis. A histopathologic definition and classification</article-title>. <source>Am J Cardiovasc Pathol</source> (<year>1987</year>) <volume>1</volume>(<issue>1</issue>):<fpage>3</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">3455232</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magnani</surname><given-names>JW</given-names></name><name><surname>Dec</surname><given-names>GW</given-names></name></person-group>
<article-title>Myocarditis: current trends in diagnosis and treatment</article-title>. <source>Circulation</source> (<year>2006</year>) <volume>113</volume>(<issue>6</issue>):<fpage>876</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.584532</pub-id><pub-id pub-id-type="pmid">16476862</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caforio</surname><given-names>AL</given-names></name><name><surname>Marcolongo</surname><given-names>R</given-names></name><name><surname>Jahns</surname><given-names>R</given-names></name><name><surname>Fu</surname><given-names>M</given-names></name><name><surname>Felix</surname><given-names>SB</given-names></name><name><surname>Iliceto</surname><given-names>S</given-names></name></person-group>. <article-title>Immune-mediated and autoimmune myocarditis: clinical presentation, diagnosis and management</article-title>. <source>Heart Fail Rev</source> (<year>2013</year>) <volume>18</volume>(<issue>6</issue>):<fpage>715</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1007/s10741-012-9364-5</pub-id><?supplied-pmid 23114995?><pub-id pub-id-type="pmid">23114995</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yajima</surname><given-names>T</given-names></name><name><surname>Knowlton</surname><given-names>KU</given-names></name></person-group>
<article-title>Viral myocarditis: from the perspective of the virus</article-title>. <source>Circulation</source> (<year>2009</year>) <volume>119</volume>(<issue>19</issue>):<fpage>2615</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.08.766022</pub-id><pub-id pub-id-type="pmid">19451363</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calabrese</surname><given-names>F</given-names></name><name><surname>Thiene</surname><given-names>G</given-names></name></person-group>. <article-title>Myocarditis and inflammatory cardiomyopathy: microbiological and molecular biological aspects</article-title>. <source>Cardiovasc Res</source> (<year>2003</year>) <volume>60</volume>(<issue>1</issue>):<fpage>11</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1016/S0008-6363(03)00475-9</pub-id><?supplied-pmid 14522403?><pub-id pub-id-type="pmid">14522403</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bock</surname><given-names>CT</given-names></name><name><surname>Klingel</surname><given-names>K</given-names></name><name><surname>Kandolf</surname><given-names>R</given-names></name></person-group>
<article-title>Human parvovirus B19-associated myocarditis</article-title>. <source>N Engl J Med</source> (<year>2010</year>) <volume>362</volume>(<issue>13</issue>):<fpage>1248</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMc0911362</pub-id><pub-id pub-id-type="pmid">20357294</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baboonian</surname><given-names>C</given-names></name><name><surname>Treasure</surname><given-names>T</given-names></name></person-group>. <article-title>Meta-analysis of the association of enteroviruses with human heart disease</article-title>. <source>Heart</source> (<year>1997</year>) <volume>78</volume>(<issue>6</issue>):<fpage>539</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1136/hrt.78.6.539</pub-id><?supplied-pmid 9470867?><pub-id pub-id-type="pmid">9470867</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maisch</surname><given-names>B</given-names></name><name><surname>Sch&#246;nian</surname><given-names>U</given-names></name><name><surname>Crombach</surname><given-names>M</given-names></name><name><surname>Wendl</surname><given-names>I</given-names></name><name><surname>Bethge</surname><given-names>C</given-names></name><name><surname>Herzum</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Cytomegalovirus associated inflammatory heart muscle disease</article-title>. <source>Scand J Infect Dis Suppl</source> (<year>1993</year>) <volume>88</volume>:<fpage>135</fpage>&#8211;<lpage>48</lpage>.<?supplied-pmid 8390717?><pub-id pub-id-type="pmid">8390717</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumori</surname><given-names>A</given-names></name><name><surname>Matoba</surname><given-names>Y</given-names></name><name><surname>Sasayama</surname><given-names>S</given-names></name></person-group>. <article-title>Dilated cardiomyopathy associated with hepatitis C virus infection</article-title>. <source>Circulation</source> (<year>1995</year>) <volume>92</volume>(<issue>9</issue>):<fpage>2519</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1161/01.CIR.92.9.2519</pub-id><?supplied-pmid 7586353?><pub-id pub-id-type="pmid">7586353</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pankuweit</surname><given-names>S</given-names></name><name><surname>Moll</surname><given-names>R</given-names></name><name><surname>Baandrup</surname><given-names>U</given-names></name><name><surname>Portig</surname><given-names>I</given-names></name><name><surname>Hufnagel</surname><given-names>G</given-names></name><name><surname>Maisch</surname><given-names>B</given-names></name></person-group>. <article-title>Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens</article-title>. <source>Hum Pathol</source> (<year>2003</year>) <volume>34</volume>(<issue>5</issue>):<fpage>497</fpage>&#8211;<lpage>503</lpage>.<pub-id pub-id-type="doi">10.1016/S0046-8177(03)00078-9</pub-id><?supplied-pmid 12792925?><pub-id pub-id-type="pmid">12792925</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#252;hl</surname><given-names>U</given-names></name><name><surname>Pauschinger</surname><given-names>M</given-names></name><name><surname>Noutsias</surname><given-names>M</given-names></name><name><surname>Seeberg</surname><given-names>B</given-names></name><name><surname>Bock</surname><given-names>T</given-names></name><name><surname>Lassner</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>High prevalence of viral genomes and multiple viral infections in the myocardium of adults with &#8220;idiopathic&#8221; left ventricular dysfunction</article-title>. <source>Circulation</source> (<year>2005</year>) <volume>111</volume>(<issue>7</issue>):<fpage>887</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="doi">10.1161/01.CIR.0000155616.07901.35</pub-id><pub-id pub-id-type="pmid">15699250</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowles</surname><given-names>NE</given-names></name><name><surname>Ni</surname><given-names>J</given-names></name><name><surname>Kearney</surname><given-names>DL</given-names></name><name><surname>Pauschinger</surname><given-names>M</given-names></name><name><surname>Schultheiss</surname><given-names>HP</given-names></name><name><surname>McCarthy</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Detection of viruses in myocardial tissues by polymerase chain reaction. evidence of adenovirus as a common cause of myocarditis in children and adults</article-title>. <source>J Am Coll Cardiol</source> (<year>2003</year>) <volume>42</volume>(<issue>3</issue>):<fpage>466</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1016/S0735-1097(03)00648-X</pub-id><?supplied-pmid 12906974?><pub-id pub-id-type="pmid">12906974</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>NR</given-names></name></person-group>. <article-title>Myocarditis: infection versus autoimmunity</article-title>. <source>J Clin Immunol</source> (<year>2009</year>) <volume>29</volume>(<issue>6</issue>):<fpage>730</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1007/s10875-009-9339-z</pub-id><?supplied-pmid 19826933?><pub-id pub-id-type="pmid">19826933</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Comarmond</surname><given-names>C</given-names></name><name><surname>Cacoub</surname><given-names>P</given-names></name></person-group>. <article-title>Myocarditis in auto-immune or auto-inflammatory diseases</article-title>. <source>Autoimmun Rev</source> (<year>2017</year>) <volume>16</volume>(<issue>8</issue>):<fpage>811</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.autrev.2017.05.021</pub-id><?supplied-pmid 28572050?><pub-id pub-id-type="pmid">28572050</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Luca</surname><given-names>G</given-names></name><name><surname>Bosello</surname><given-names>S</given-names></name><name><surname>Leone</surname><given-names>AM</given-names></name><name><surname>Gabrielli</surname><given-names>F</given-names></name><name><surname>Pelargonio</surname><given-names>G</given-names></name><name><surname>Inzani</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Life-threatening arrhythmias in a scleroderma patient: the role of myocardial inflammation in arrhythmic outburst</article-title>. <source>Scand J Rheumatol</source> (<year>2017</year>) <volume>46</volume>(<issue>1</issue>):<fpage>78</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.3109/03009742.2016.1157626</pub-id><pub-id pub-id-type="pmid">27098649</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pieroni</surname><given-names>M</given-names></name><name><surname>De Santis</surname><given-names>M</given-names></name><name><surname>Zizzo</surname><given-names>G</given-names></name><name><surname>Bosello</surname><given-names>S</given-names></name><name><surname>Smaldone</surname><given-names>C</given-names></name><name><surname>Campioni</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression</article-title>. <source>Semin Arthritis Rheum</source> (<year>2014</year>) <volume>43</volume>(<issue>4</issue>):<fpage>526</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1016/j.semarthrit.2013.07.006</pub-id><?supplied-pmid 23932313?><pub-id pub-id-type="pmid">23932313</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Luca</surname><given-names>G</given-names></name><name><surname>Bosello</surname><given-names>SL</given-names></name><name><surname>Gabrielli</surname><given-names>FA</given-names></name><name><surname>Berardi</surname><given-names>G</given-names></name><name><surname>Parisi</surname><given-names>F</given-names></name><name><surname>Rucco</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Prognostic role of ventricular ectopic beats in systemic sclerosis: a prospective cohort study shows ECG indexes predicting the worse outcome</article-title>. <source>PLoS One</source> (<year>2016</year>) <volume>11</volume>(<issue>4</issue>):<fpage>e0153012</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0153012</pub-id><?supplied-pmid 27101136?><pub-id pub-id-type="pmid">27101136</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosello</surname><given-names>S</given-names></name><name><surname>De Luca</surname><given-names>G</given-names></name><name><surname>Ferraccioli</surname><given-names>G</given-names></name></person-group>
<article-title>Troponin in stable ischemic heart disease and diabetes</article-title>. <source>N Engl J Med</source> (<year>2015</year>) <volume>373</volume>(<issue>20</issue>):<fpage>1977</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMc1511645#SA4</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colafrancesco</surname><given-names>S</given-names></name><name><surname>Priori</surname><given-names>R</given-names></name><name><surname>Valesini</surname><given-names>G</given-names></name><name><surname>Argolini</surname><given-names>L</given-names></name><name><surname>Baldissera</surname><given-names>E</given-names></name><name><surname>Bartoloni</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Response to interleukin-1 inhibitors in 140 italian patients with adult-onset still&#8217;s disease: a multicentre retrospective observational study</article-title>. <source>Front Pharmacol</source> (<year>2017</year>) <volume>8</volume>:<fpage>369</fpage>.<pub-id pub-id-type="doi">10.3389/fphar.2017.00369</pub-id><?supplied-pmid 28659802?><pub-id pub-id-type="pmid">28659802</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Luca</surname><given-names>G</given-names></name><name><surname>Bosello</surname><given-names>SL</given-names></name><name><surname>Canestrari</surname><given-names>G</given-names></name><name><surname>Cavalli</surname><given-names>G</given-names></name><name><surname>Dagna</surname><given-names>L</given-names></name><name><surname>Ferraccioli</surname><given-names>G</given-names></name></person-group>
<article-title>QTc interval prolongation in systemic sclerosis: correlations with clinical variables and arrhythmic risk</article-title>. <source>Int J Cardiol</source> (<year>2017</year>) <volume>239</volume>:<fpage>33</fpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2017.03.088</pub-id><pub-id pub-id-type="pmid">28560978</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campochiaro</surname><given-names>C</given-names></name><name><surname>Tomelleri</surname><given-names>A</given-names></name><name><surname>Cavalli</surname><given-names>G</given-names></name><name><surname>Berti</surname><given-names>A</given-names></name><name><surname>Dagna</surname><given-names>L</given-names></name></person-group>. <article-title>Erdheim-Chester disease</article-title>. <source>Eur J Intern Med</source> (<year>2015</year>) <volume>26</volume>(<issue>4</issue>):<fpage>223</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.ejim.2015.03.004</pub-id><?supplied-pmid 25865950?><pub-id pub-id-type="pmid">25865950</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Root-Bernstein</surname><given-names>R</given-names></name><name><surname>Fairweather</surname><given-names>D</given-names></name></person-group>. <article-title>Unresolved issues in theories of autoimmune disease using myocarditis as a framework</article-title>. <source>J Theor Biol</source> (<year>2015</year>) <volume>375</volume>:<fpage>101</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1016/j.jtbi.2014.11.022</pub-id><?supplied-pmid 25484004?><pub-id pub-id-type="pmid">25484004</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fairweather</surname><given-names>D</given-names></name><name><surname>Rose</surname><given-names>NR</given-names></name></person-group>. <article-title>Coxsackievirus-induced myocarditis in mice: a model of autoimmune disease for studying immunotoxicity</article-title>. <source>Methods</source> (<year>2007</year>) <volume>41</volume>(<issue>1</issue>):<fpage>118</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1016/j.ymeth.2006.07.009</pub-id><?supplied-pmid 17161308?><pub-id pub-id-type="pmid">17161308</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felker</surname><given-names>GM</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Hare</surname><given-names>JM</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Baughman</surname><given-names>KL</given-names></name><name><surname>Kasper</surname><given-names>EK</given-names></name></person-group>. <article-title>The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1,278 patients</article-title>. <source>Medicine (Baltimore)</source> (<year>1999</year>) <volume>78</volume>(<issue>4</issue>):<fpage>270</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1097/00005792-199907000-00005</pub-id><?supplied-pmid 10424207?><pub-id pub-id-type="pmid">10424207</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Towbin</surname><given-names>JA</given-names></name><name><surname>Lowe</surname><given-names>AM</given-names></name><name><surname>Colan</surname><given-names>SD</given-names></name><name><surname>Sleeper</surname><given-names>LA</given-names></name><name><surname>Orav</surname><given-names>EJ</given-names></name><name><surname>Clunie</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Incidence, causes, and outcomes of dilated cardiomyopathy in children</article-title>. <source>JAMA</source> (<year>2006</year>) <volume>296</volume>(<issue>15</issue>):<fpage>1867</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="doi">10.1001/jama.296.15.1867</pub-id><?supplied-pmid 17047217?><pub-id pub-id-type="pmid">17047217</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kindermann</surname><given-names>I</given-names></name><name><surname>Barth</surname><given-names>C</given-names></name><name><surname>Mahfoud</surname><given-names>F</given-names></name><name><surname>Ukena</surname><given-names>C</given-names></name><name><surname>Lenski</surname><given-names>M</given-names></name><name><surname>Yilmaz</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Update on myocarditis</article-title>. <source>J Am Coll Cardiol</source> (<year>2012</year>) <volume>59</volume>(<issue>9</issue>):<fpage>779</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="doi">10.1016/j.jacc.2011.09.074</pub-id><?supplied-pmid 22361396?><pub-id pub-id-type="pmid">22361396</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caforio</surname><given-names>AL</given-names></name><name><surname>Pankuweit</surname><given-names>S</given-names></name><name><surname>Arbustini</surname><given-names>E</given-names></name><name><surname>Basso</surname><given-names>C</given-names></name><name><surname>Gimeno-Blanes</surname><given-names>J</given-names></name><name><surname>Felix</surname><given-names>SB</given-names></name><etal/></person-group>
<article-title>European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases</article-title>. <source>Eur Heart J</source> (<year>2013</year>) <volume>34</volume>(<issue>33</issue>):<fpage>2648a</fpage>&#8211;<lpage>2648d</lpage>.<pub-id pub-id-type="doi">10.1093/eurheartj/eht210</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollack</surname><given-names>A</given-names></name><name><surname>Kontorovich</surname><given-names>AR</given-names></name><name><surname>Fuster</surname><given-names>V</given-names></name><name><surname>Dec</surname><given-names>GW</given-names></name></person-group>
<article-title>Viral myocarditis &#8211; diagnosis, treatment options, and current controversies</article-title>. <source>Nat Rev Cardiol</source> (<year>2015</year>) <volume>12</volume>(<issue>11</issue>):<fpage>670</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1038/nrcardio.2015.108</pub-id><pub-id pub-id-type="pmid">26194549</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabre</surname><given-names>A</given-names></name><name><surname>Sheppard</surname><given-names>MN</given-names></name></person-group>. <article-title>Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death</article-title>. <source>Heart</source> (<year>2006</year>) <volume>92</volume>(<issue>3</issue>):<fpage>316</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1136/hrt.2004.045518</pub-id><?supplied-pmid 15923280?><pub-id pub-id-type="pmid">15923280</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bracamonte-Baran</surname><given-names>W</given-names></name><name><surname>&#268;ih&#225;kov&#225;</surname><given-names>D</given-names></name></person-group>. <article-title>Cardiac autoimmunity: myocarditis</article-title>. <source>Adv Exp Med Biol</source> (<year>2017</year>) <volume>1003</volume>:<fpage>187</fpage>&#8211;<lpage>221</lpage>.<pub-id pub-id-type="doi">10.1007/978-3-319-57613-8_10</pub-id><?supplied-pmid 28667560?><pub-id pub-id-type="pmid">28667560</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavalli</surname><given-names>G</given-names></name><name><surname>Hayashi</surname><given-names>M</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Yorgov</surname><given-names>D</given-names></name><name><surname>Santorico</surname><given-names>SA</given-names></name><name><surname>Holcomb</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2016</year>) <volume>113</volume>(<issue>5</issue>):<fpage>1363</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1523482113</pub-id><?supplied-pmid 26787888?><pub-id pub-id-type="pmid">26787888</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>M</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Yorgov</surname><given-names>D</given-names></name><name><surname>Santorico</surname><given-names>SA</given-names></name><name><surname>Hagman</surname><given-names>J</given-names></name><name><surname>Ferrara</surname><given-names>TM</given-names></name><etal/></person-group>
<article-title>Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression of HLA-A*02:01 in vivo</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2016</year>) <volume>113</volume>(<issue>5</issue>):<fpage>1357</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1525001113</pub-id><?supplied-pmid 26787886?><pub-id pub-id-type="pmid">26787886</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group>. <article-title>Interleukin-1 in the pathogenesis and treatment of inflammatory diseases</article-title>. <source>Blood</source> (<year>2011</year>) <volume>117</volume>(<issue>14</issue>):<fpage>3720</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2010-07-273417</pub-id><?supplied-pmid 21304099?><pub-id pub-id-type="pmid">21304099</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bujak</surname><given-names>M</given-names></name><name><surname>Frangogiannis</surname><given-names>NG</given-names></name></person-group>. <article-title>The role of IL-1 in the pathogenesis of heart disease</article-title>. <source>Arch Immunol Ther Exp (Warsz)</source> (<year>2009</year>) <volume>57</volume>(<issue>3</issue>):<fpage>165</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="doi">10.1007/s00005-009-0024-y</pub-id><?supplied-pmid 19479203?><pub-id pub-id-type="pmid">19479203</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavalli</surname><given-names>G</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group>. <article-title>Suppression of inflammation and acquired immunity by IL-37</article-title>. <source>Immunol Rev</source> (<year>2018</year>) <volume>281</volume>(<issue>1</issue>):<fpage>179</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1111/imr.12605</pub-id><?supplied-pmid 29247987?><pub-id pub-id-type="pmid">29247987</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavalli</surname><given-names>G</given-names></name><name><surname>Justice</surname><given-names>JN</given-names></name><name><surname>Boyle</surname><given-names>KE</given-names></name><name><surname>D&#8217;Alessandro</surname><given-names>A</given-names></name><name><surname>Eisenmesser</surname><given-names>EZ</given-names></name><name><surname>Herrera</surname><given-names>JJ</given-names></name><etal/></person-group>
<article-title>Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2017</year>) <volume>114</volume>(<issue>9</issue>):<fpage>2313</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1619011114</pub-id><?supplied-pmid 28193888?><pub-id pub-id-type="pmid">28193888</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toldo</surname><given-names>S</given-names></name><name><surname>Kannan</surname><given-names>H</given-names></name><name><surname>Bussani</surname><given-names>R</given-names></name><name><surname>Anzini</surname><given-names>M</given-names></name><name><surname>Sonnino</surname><given-names>C</given-names></name><name><surname>Sinagra</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Formation of the inflammasome in acute myocarditis</article-title>. <source>Int J Cardiol</source> (<year>2014</year>) <volume>171</volume>(<issue>3</issue>):<fpage>e119</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="doi">10.1016/j.ijcard.2013.12.137</pub-id><pub-id pub-id-type="pmid">24439778</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbate</surname><given-names>A</given-names></name></person-group>
<article-title>The heart on fire: inflammasome and cardiomyopathy</article-title>. <source>Exp Physiol</source> (<year>2013</year>) <volume>98</volume>(<issue>2</issue>):<fpage>385</fpage><pub-id pub-id-type="doi">10.1113/expphysiol.2012.069021</pub-id><pub-id pub-id-type="pmid">23349530</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Tassell</surname><given-names>BW</given-names></name><name><surname>Toldo</surname><given-names>S</given-names></name><name><surname>Mezzaroma</surname><given-names>E</given-names></name><name><surname>Abbate</surname><given-names>A</given-names></name></person-group>
<article-title>Targeting interleukin-1 in heart disease</article-title>. <source>Circulation</source> (<year>2013</year>) <volume>128</volume>(<issue>17</issue>):<fpage>1910</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.113.003199</pub-id><pub-id pub-id-type="pmid">24146121</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>MK</given-names></name><name><surname>Gulick</surname><given-names>TS</given-names></name><name><surname>Rotondo</surname><given-names>RE</given-names></name><name><surname>Schreiner</surname><given-names>GF</given-names></name><name><surname>Lange</surname><given-names>LG</given-names></name></person-group>. <article-title>Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiacmyocytes. Impairment of signal transduction</article-title>. <source>Circ Res</source> (<year>1990</year>) <volume>67</volume>:<fpage>753</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1161/01.RES.67.3.753</pub-id><?supplied-pmid 2168817?><pub-id pub-id-type="pmid">2168817</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>SJ</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Kennedy</surname><given-names>RH</given-names></name></person-group>. <article-title>Suppression of beta-adrenergic responsiveness of L-type Ca2+ current by IL-1beta in rat ventricular myocytes</article-title>. <source>Am J Physiol</source> (<year>1999</year>) <volume>276</volume>:<fpage>H141</fpage>&#8211;<lpage>8</lpage>.<?supplied-pmid 9887027?><pub-id pub-id-type="pmid">9887027</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schreur</surname><given-names>KD</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name></person-group>. <article-title>Involvement of ceramide in inhibitory effect of IL-1 beta on L-type Ca2+ current in adult rat ventricular myocytes</article-title>. <source>Am J Physiol</source> (<year>1997</year>) <volume>272</volume>:<fpage>H2591</fpage>&#8211;<lpage>8</lpage>.<?supplied-pmid 9227535?><pub-id pub-id-type="pmid">9227535</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Schreur</surname><given-names>KD</given-names></name></person-group>. <article-title>G protein-mediated suppression of L-type Ca2+ current by interleukin-1 beta in cultured rat ventricular myocytes</article-title>. <source>Am J Physiol</source> (<year>1995</year>) <volume>268</volume>:<fpage>C339</fpage>&#8211;<lpage>49</lpage>.<pub-id pub-id-type="doi">10.1152/ajpcell.1995.268.2.C339</pub-id><?supplied-pmid 7864073?><pub-id pub-id-type="pmid">7864073</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Combes</surname><given-names>A</given-names></name><name><surname>Frye</surname><given-names>CS</given-names></name><name><surname>Lemster</surname><given-names>BH</given-names></name><name><surname>Brooks</surname><given-names>SS</given-names></name><name><surname>Watkins</surname><given-names>SC</given-names></name><name><surname>Feldman</surname><given-names>AM</given-names></name><etal/></person-group>
<article-title>Chronic exposure to interleukin 1beta induces a delayed and reversible alteration in excitation-contraction coupling of cultured cardiomyocytes</article-title>. <source>Pflugers Arch</source> (<year>2002</year>) <volume>445</volume>(<issue>2</issue>):<fpage>246</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="doi">10.1007/s00424-002-0921-y</pub-id><?supplied-pmid 12457245?><pub-id pub-id-type="pmid">12457245</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McTiernan</surname><given-names>CF</given-names></name><name><surname>Lemster</surname><given-names>BH</given-names></name><name><surname>Frye</surname><given-names>C</given-names></name><name><surname>Brooks</surname><given-names>S</given-names></name><name><surname>Combes</surname><given-names>A</given-names></name><name><surname>Feldman</surname><given-names>AM</given-names></name></person-group>. <article-title>Interleukin-1 beta inhibits phospholamban gene expression in cultured cardiomyocytes</article-title>. <source>Circ Res</source> (<year>1997</year>) <volume>81</volume>:<fpage>493</fpage>&#8211;<lpage>503</lpage>.<pub-id pub-id-type="doi">10.1161/01.RES.81.4.493</pub-id><?supplied-pmid 9314830?><pub-id pub-id-type="pmid">9314830</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tatsumi</surname><given-names>T</given-names></name><name><surname>Matoba</surname><given-names>S</given-names></name><name><surname>Kawahara</surname><given-names>A</given-names></name><name><surname>Keira</surname><given-names>N</given-names></name><name><surname>Shiraishi</surname><given-names>J</given-names></name><name><surname>Akashi</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes</article-title>. <source>J Am Coll Cardiol</source> (<year>2000</year>) <volume>35</volume>:<fpage>1338</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="doi">10.1016/S0735-1097(00)00526-X</pub-id><?supplied-pmid 10758978?><pub-id pub-id-type="pmid">10758978</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>R</given-names></name><name><surname>Panas</surname><given-names>DL</given-names></name><name><surname>Catena</surname><given-names>R</given-names></name><name><surname>Moncada</surname><given-names>S</given-names></name><name><surname>Olley</surname><given-names>PM</given-names></name><name><surname>Lopaschuk</surname><given-names>GD</given-names></name></person-group>. <article-title>The role of nitric oxide in cardiac depression induced by interleukin-1 beta and tumour necrosis factor-alpha</article-title>. <source>Br J Pharmacol</source> (<year>1995</year>) <volume>114</volume>:<fpage>27</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="doi">10.1111/j.1476-5381.1995.tb14901.x</pub-id><?supplied-pmid 7536096?><pub-id pub-id-type="pmid">7536096</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsujino</surname><given-names>M</given-names></name><name><surname>Hirata</surname><given-names>Y</given-names></name><name><surname>Imai</surname><given-names>T</given-names></name><name><surname>Kanno</surname><given-names>K</given-names></name><name><surname>Eguchi</surname><given-names>S</given-names></name><name><surname>Ito</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Induction of nitric oxide synthase gene by interleukin-1 beta in cultured rat cardiocytes</article-title>. <source>Circulation</source> (<year>1994</year>) <volume>90</volume>:<fpage>375</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1161/01.CIR.90.1.375</pub-id><?supplied-pmid 7517798?><pub-id pub-id-type="pmid">7517798</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Tassell</surname><given-names>BW</given-names></name><name><surname>Arena</surname><given-names>RA</given-names></name><name><surname>Toldo</surname><given-names>S</given-names></name><name><surname>Mezzaroma</surname><given-names>E</given-names></name><name><surname>Azam</surname><given-names>T</given-names></name><name><surname>Seropian</surname><given-names>IM</given-names></name><etal/></person-group>
<article-title>Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure</article-title>. <source>PLoS One</source> (<year>2012</year>) <volume>7</volume>(<issue>3</issue>):<fpage>e33438</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0033438</pub-id><pub-id pub-id-type="pmid">22438931</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toldo</surname><given-names>S</given-names></name><name><surname>Mezzaroma</surname><given-names>E</given-names></name><name><surname>O&#8217;Brien</surname><given-names>L</given-names></name><name><surname>Marchetti</surname><given-names>C</given-names></name><name><surname>Seropian</surname><given-names>IM</given-names></name><name><surname>Voelkel</surname><given-names>NF</given-names></name><etal/></person-group>
<article-title>Interleukin-18 mediates interleukin-1-induced cardiac dysfunction</article-title>. <source>Am J Physiol Heart Circ Physiol</source> (<year>2014</year>) <volume>306</volume>(<issue>7</issue>):<fpage>H1025</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1152/ajpheart.00795.2013</pub-id><?supplied-pmid 24531812?><pub-id pub-id-type="pmid">24531812</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toldo</surname><given-names>S</given-names></name><name><surname>Mezzaroma</surname><given-names>E</given-names></name><name><surname>Bressi</surname><given-names>E</given-names></name><name><surname>Marchetti</surname><given-names>C</given-names></name><name><surname>Carbone</surname><given-names>S</given-names></name><name><surname>Sonnino</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Interleukin-1&#946; blockade improves left ventricular systolic/ diastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse</article-title>. <source>J Cardiovasc Pharmacol</source> (<year>2014</year>) <volume>64</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1097/FJC.0000000000000106</pub-id><pub-id pub-id-type="pmid">25006675</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Thota</surname><given-names>V</given-names></name><name><surname>Dee</surname><given-names>L</given-names></name><name><surname>Olson</surname><given-names>J</given-names></name><name><surname>Uretz</surname><given-names>E</given-names></name><name><surname>Parrillo</surname><given-names>JE</given-names></name></person-group>. <article-title>Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum</article-title>. <source>J Exp Med</source> (<year>1996</year>) <volume>183</volume>(<issue>3</issue>):<fpage>949</fpage>&#8211;<lpage>58</lpage>.<pub-id pub-id-type="doi">10.1084/jem.183.3.949</pub-id><?supplied-pmid 8642298?><pub-id pub-id-type="pmid">8642298</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>JR</given-names></name><name><surname>Neumann</surname><given-names>DA</given-names></name><name><surname>Lafond-Walker</surname><given-names>A</given-names></name><name><surname>Herskowitz</surname><given-names>A</given-names></name><name><surname>Rose</surname><given-names>NR</given-names></name></person-group>. <article-title>Role of IL-1 and tumor necrosis factor in coxsackie virus-induced autoimmune myocarditis</article-title>. <source>J Immunol</source> (<year>1993</year>) <volume>151</volume>:<fpage>1682</fpage>&#8211;<lpage>90</lpage>.<?supplied-pmid 8335952?><pub-id pub-id-type="pmid">8335952</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shioi</surname><given-names>T</given-names></name><name><surname>Matsumori</surname><given-names>A</given-names></name><name><surname>Sasayama</surname><given-names>S</given-names></name></person-group>. <article-title>Persistent expression of cytokine in the chronic stage of viral myocarditis in mice</article-title>. <source>Circulation</source> (<year>1996</year>) <volume>94</volume>:<fpage>2930</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1161/01.CIR.94.11.2930</pub-id><?supplied-pmid 8941123?><pub-id pub-id-type="pmid">8941123</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>RO</given-names></name><name><surname>Ray</surname><given-names>PE</given-names></name><name><surname>Baughman</surname><given-names>KL</given-names></name><name><surname>Feldman</surname><given-names>AM</given-names></name></person-group>. <article-title>Detection of interleukin and interleukin-receptor mRNA in human heart by polymerase chain reaction</article-title>. <source>Biochem Biophys Res Commun</source> (<year>1991</year>) <volume>181</volume>:<fpage>520</fpage>&#8211;<lpage>3</lpage>.<pub-id pub-id-type="doi">10.1016/0006-291X(91)91219-3</pub-id><?supplied-pmid 1836725?><pub-id pub-id-type="pmid">1836725</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanderheyden</surname><given-names>M</given-names></name><name><surname>Paulus</surname><given-names>WJ</given-names></name><name><surname>Voss</surname><given-names>M</given-names></name><name><surname>Knuefermann</surname><given-names>P</given-names></name><name><surname>Sivasubramanian</surname><given-names>N</given-names></name><name><surname>Mann</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Myocardial cytokine gene expression is higher in aortic stenosis than in idiopathic dilated cardiomyopathy</article-title>. <source>Heart</source> (<year>2005</year>) <volume>91</volume>:<fpage>926</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1136/hrt.2004.035733</pub-id><?supplied-pmid 15958363?><pub-id pub-id-type="pmid">15958363</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eriksson</surname><given-names>U</given-names></name><name><surname>Kurrer</surname><given-names>MO</given-names></name><name><surname>Sonderegger</surname><given-names>I</given-names></name><name><surname>Iezzi</surname><given-names>G</given-names></name><name><surname>Tafuri</surname><given-names>A</given-names></name><name><surname>Hunziker</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Activation of dendritic cells through the interleukin 1 receptor 1 is critical for the induction of autoimmune myocarditis</article-title>. <source>J Exp Med</source> (<year>2003</year>) <volume>197</volume>:<fpage>323</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20021788</pub-id><?supplied-pmid 12566416?><pub-id pub-id-type="pmid">12566416</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>BK</given-names></name><name><surname>Choe</surname><given-names>SC</given-names></name><name><surname>Shin</surname><given-names>JO</given-names></name><name><surname>Ho</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>JM</given-names></name><name><surname>Yu</surname><given-names>SS</given-names></name><etal/></person-group>
<article-title>Local expression of interleukin-1 receptor antagonist by plasmid DNA improves mortality and decreases myocardial inflammation in experimental coxsackieviral myocarditis</article-title>. <source>Circulation</source> (<year>2002</year>) <volume>105</volume>:<fpage>1278</fpage>&#8211;<lpage>81</lpage>.<?supplied-pmid 11901035?><pub-id pub-id-type="pmid">11901035</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Hanawa</surname><given-names>H</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Elnaggar</surname><given-names>R</given-names></name><name><surname>Hayashi</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Effect of hydrodynamics-based gene delivery of plasmid DNA encoding interleukin-1 receptor antagonist-Ig for treatment of rat autoimmune myocarditis: possible mechanism for lymphocytes and noncardiac cells</article-title>. <source>Circulation</source> (<year>2005</year>) <volume>111</volume>:<fpage>1593</fpage>&#8211;<lpage>600</lpage>.<pub-id pub-id-type="doi">10.1161/01.CIR.0000160348.75918.CA</pub-id><?supplied-pmid 15795329?><pub-id pub-id-type="pmid">15795329</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavalli</surname><given-names>G</given-names></name><name><surname>Franchini</surname><given-names>S</given-names></name><name><surname>Aiello</surname><given-names>P</given-names></name><name><surname>Guglielmi</surname><given-names>B</given-names></name><name><surname>Berti</surname><given-names>A</given-names></name><name><surname>Campochiaro</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Efficacy and safety of biological agents in adult-onset still&#8217;s disease</article-title>. <source>Scand J Rheumatol</source> (<year>2015</year>) <volume>44</volume>(<issue>4</issue>):<fpage>309</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="doi">10.3109/03009742.2014.992949</pub-id><?supplied-pmid 25656459?><pub-id pub-id-type="pmid">25656459</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavalli</surname><given-names>G</given-names></name><name><surname>De Luca</surname><given-names>G</given-names></name><name><surname>Dagna</surname><given-names>L</given-names></name></person-group>
<article-title>Advances in potential targeted therapies for Erdheim-Chester disease</article-title>. <source>Expert Opin Orphan Drugs</source> (<year>2017</year>) <volume>5</volume>(<issue>3</issue>):<fpage>253</fpage>&#8211;<lpage>60</lpage>.</mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavalli</surname><given-names>G</given-names></name><name><surname>Fallanca</surname><given-names>F</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Dagna</surname><given-names>L</given-names></name></person-group>
<article-title>Treating pulmonary silicosis by blocking interleukin 1</article-title>. <source>Am J Respir Crit Care Med</source> (<year>2015</year>) <volume>191</volume>(<issue>5</issue>):<fpage>596</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1164/rccm.201412-2150LE</pub-id><pub-id pub-id-type="pmid">25723826</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavalli</surname><given-names>G</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group>. <article-title>Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies</article-title>. <source>Rheumatology (Oxford)</source> (<year>2015</year>) <volume>54</volume>(<issue>12</issue>):<fpage>2134</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1093/rheumatology/kev269</pub-id><?supplied-pmid 26209330?><pub-id pub-id-type="pmid">26209330</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Priori</surname><given-names>SG</given-names></name><name><surname>Blomstr&#246;m-Lundqvist</surname><given-names>C</given-names></name><name><surname>Mazzanti</surname><given-names>A</given-names></name><name><surname>Blom</surname><given-names>N</given-names></name><name><surname>Borggrefe</surname><given-names>M</given-names></name><name><surname>Camm</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European society of cardiology (ESC). 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European society of cardiology (ESC)endorsed by: association for European paediatric and congenital cardiology (AEPC)</article-title>. <source>Europace</source> (<year>2015</year>) <volume>17</volume>(<issue>11</issue>):<fpage>1601</fpage>&#8211;<lpage>87</lpage>.<pub-id pub-id-type="doi">10.1093/europace/euv319</pub-id><pub-id pub-id-type="pmid">26318695</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponikowski</surname><given-names>P</given-names></name><name><surname>Voors</surname><given-names>AA</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Bueno</surname><given-names>H</given-names></name><name><surname>Cleland</surname><given-names>JG</given-names></name><name><surname>Coats</surname><given-names>AJ</given-names></name><etal/></person-group>
<article-title>Authors/task force members; document reviewers. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC</article-title>. <source>Eur J Heart Fail</source> (<year>2016</year>) <volume>18</volume>(<issue>8</issue>):<fpage>891</fpage>&#8211;<lpage>975</lpage>.<pub-id pub-id-type="doi">10.1002/ejhf.592</pub-id><pub-id pub-id-type="pmid">27207191</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frustaci</surname><given-names>A</given-names></name><name><surname>Chimenti</surname><given-names>C</given-names></name><name><surname>Calabrese</surname><given-names>F</given-names></name><name><surname>Pieroni</surname><given-names>M</given-names></name><name><surname>Thiene</surname><given-names>G</given-names></name><name><surname>Maseri</surname><given-names>A</given-names></name></person-group>. <article-title>Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders</article-title>. <source>Circulation</source> (<year>2003</year>) <volume>107</volume>(<issue>6</issue>):<fpage>857</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1161/01.CIR.0000048147.15962.31</pub-id><?supplied-pmid 12591756?><pub-id pub-id-type="pmid">12591756</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frustaci</surname><given-names>A</given-names></name><name><surname>Russo</surname><given-names>MA</given-names></name><name><surname>Chimenti</surname><given-names>C</given-names></name></person-group>. <article-title>Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study</article-title>. <source>Eur Heart J</source> (<year>2009</year>) <volume>30</volume>(<issue>16</issue>):<fpage>1995</fpage>&#8211;<lpage>2002</lpage>.<pub-id pub-id-type="doi">10.1093/eurheartj/ehp249</pub-id><?supplied-pmid 19556262?><pub-id pub-id-type="pmid">19556262</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>LT</given-names><suffix>Jr</suffix></name><name><surname>Hare</surname><given-names>JM</given-names></name><name><surname>Tazelaar</surname><given-names>HD</given-names></name><name><surname>Edwards</surname><given-names>WD</given-names></name><name><surname>Starling</surname><given-names>RC</given-names></name><name><surname>Deng</surname><given-names>MC</given-names></name><etal/></person-group>
<article-title>Giant cell myocarditis treatment trial investigators. Usefulness of immunosuppression for giant cell myocarditis</article-title>. <source>Am J Cardiol</source> (<year>2008</year>) <volume>102</volume>(<issue>11</issue>):<fpage>1535</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.amjcard.2008.07.041</pub-id><pub-id pub-id-type="pmid">19026310</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahrholdt</surname><given-names>H</given-names></name><name><surname>Goedecke</surname><given-names>C</given-names></name><name><surname>Wagner</surname><given-names>A</given-names></name><name><surname>Meinhardt</surname><given-names>G</given-names></name><name><surname>Athanasiadis</surname><given-names>A</given-names></name><name><surname>Vogelsberg</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology</article-title>. <source>Circulation</source> (<year>2004</year>) <volume>109</volume>(<issue>10</issue>):<fpage>1250</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1161/01.CIR.0000118493.13323.81</pub-id><?supplied-pmid 14993139?><pub-id pub-id-type="pmid">14993139</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escher</surname><given-names>F</given-names></name><name><surname>K&#252;hl</surname><given-names>U</given-names></name><name><surname>Lassner</surname><given-names>D</given-names></name><name><surname>Poller</surname><given-names>W</given-names></name><name><surname>Westermann</surname><given-names>D</given-names></name><name><surname>Pieske</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy</article-title>. <source>Clin Res Cardiol</source> (<year>2016</year>) <volume>105</volume>(<issue>12</issue>):<fpage>1011</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1007/s00392-016-1011-z</pub-id><?supplied-pmid 27312326?><pub-id pub-id-type="pmid">27312326</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caforio</surname><given-names>ALP</given-names></name><name><surname>Malipiero</surname><given-names>G</given-names></name><name><surname>Marcolongo</surname><given-names>R</given-names></name><name><surname>Iliceto</surname><given-names>S</given-names></name></person-group>. <article-title>Myocarditis: a clinical overview</article-title>. <source>Curr Cardiol Rep</source> (<year>2017</year>) <volume>19</volume>(<issue>7</issue>):<fpage>63</fpage>.<pub-id pub-id-type="doi">10.1007/s11886-017-0870-x</pub-id><?supplied-pmid 28540649?><pub-id pub-id-type="pmid">28540649</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Everett</surname><given-names>BM</given-names></name><name><surname>Thuren</surname><given-names>T</given-names></name><name><surname>MacFadyen</surname><given-names>JG</given-names></name><name><surname>Chang</surname><given-names>WH</given-names></name><name><surname>Ballantyne</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>CANTOS trial group. Antiinflammatory therapy with canakinumab for atherosclerotic disease</article-title>. <source>N Engl J Med</source> (<year>2017</year>) <volume>377</volume>(<issue>12</issue>):<fpage>1119</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMoa1707914</pub-id><pub-id pub-id-type="pmid">28845751</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbate</surname><given-names>A</given-names></name><name><surname>Kontos</surname><given-names>MC</given-names></name><name><surname>Grizzard</surname><given-names>JD</given-names></name><name><surname>Biondi-Zoccai</surname><given-names>GG</given-names></name><name><surname>Van Tassell</surname><given-names>BW</given-names></name><name><surname>Robati</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study)</article-title>. <source>Am J Cardiol</source> (<year>2010</year>) <volume>105</volume>(<issue>10</issue>):<fpage>1371</fpage>&#8211;<lpage>1377.e1</lpage>.<pub-id pub-id-type="doi">10.1016/j.amjcard.2009.12.059</pub-id><pub-id pub-id-type="pmid">20451681</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbate</surname><given-names>A</given-names></name><name><surname>Van Tassell</surname><given-names>BW</given-names></name><name><surname>Biondi-Zoccai</surname><given-names>G</given-names></name><name><surname>Kontos</surname><given-names>MC</given-names></name><name><surname>Grizzard</surname><given-names>JD</given-names></name><name><surname>Spillman</surname><given-names>DW</given-names></name><etal/></person-group>
<article-title>Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCUART2) pilot study]</article-title>. <source>Am J Cardiol</source> (<year>2013</year>) <volume>111</volume>(<issue>10</issue>):<fpage>1394</fpage>&#8211;<lpage>400</lpage>.<pub-id pub-id-type="doi">10.1016/j.amjcard.2013.01.287</pub-id><pub-id pub-id-type="pmid">23453459</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morton</surname><given-names>AC</given-names></name><name><surname>Rothman</surname><given-names>AM</given-names></name><name><surname>Greenwood</surname><given-names>JP</given-names></name><name><surname>Gunn</surname><given-names>J</given-names></name><name><surname>Chase</surname><given-names>A</given-names></name><name><surname>Clarke</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRCILA Heart Study</article-title>. <source>Eur Heart J</source> (<year>2015</year>) <volume>36</volume>(<issue>6</issue>):<fpage>377</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1093/eurheartj/ehu272</pub-id><pub-id pub-id-type="pmid">25079365</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Tassell</surname><given-names>BW</given-names></name><name><surname>Buckley</surname><given-names>LF</given-names></name><name><surname>Carbone</surname><given-names>S</given-names></name><name><surname>Trankle</surname><given-names>CR</given-names></name><name><surname>Canada</surname><given-names>JM</given-names></name><name><surname>Dixon</surname><given-names>DL</given-names></name><etal/></person-group>
<article-title>Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the diastolic heart failure anakinra response trial 2 (D-HART2)</article-title>. <source>Clin Cardiol</source> (<year>2017</year>) <volume>40</volume>(<issue>9</issue>):<fpage>626</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1002/clc.22719</pub-id><?supplied-pmid 28475816?><pub-id pub-id-type="pmid">28475816</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Tassell</surname><given-names>BW</given-names></name><name><surname>Abouzaki</surname><given-names>NA</given-names></name><name><surname>Oddi Erdle</surname><given-names>C</given-names></name><name><surname>Carbone</surname><given-names>S</given-names></name><name><surname>Trankle</surname><given-names>CR</given-names></name><name><surname>Melchior</surname><given-names>RD</given-names></name><etal/></person-group>
<article-title>Interleukin-1 blockade in acute decompensated heart failure: a randomized, double-blinded, placebo-controlled pilot study</article-title>. <source>J Cardiovasc Pharmacol</source> (<year>2016</year>) <volume>67</volume>(<issue>6</issue>):<fpage>544</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="doi">10.1097/FJC.0000000000000378</pub-id><?supplied-pmid 26906034?><pub-id pub-id-type="pmid">26906034</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>MacFadyen</surname><given-names>JG</given-names></name><name><surname>Everett</surname><given-names>BM</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Thuren</surname><given-names>T</given-names></name><name><surname>Glynn</surname><given-names>RJ</given-names></name><etal/></person-group>
<article-title>Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial</article-title>. <source>Lancet</source> (<year>2018</year>) <volume>391</volume>(<issue>10118</issue>):<fpage>319</fpage>&#8211;<lpage>28</lpage>.<pub-id pub-id-type="doi">10.1016/S0140-6736(17)32814-3</pub-id><pub-id pub-id-type="pmid">29146124</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cain</surname><given-names>BS</given-names></name><name><surname>Meldrum</surname><given-names>DR</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Joo</surname><given-names>KS</given-names></name><name><surname>Banerjee</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function</article-title>. <source>Crit Care Med</source> (<year>1999</year>) <volume>27</volume>(<issue>7</issue>):<fpage>1309</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="doi">10.1097/00003246-199907000-00018</pub-id><?supplied-pmid 10446825?><pub-id pub-id-type="pmid">10446825</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Tassell</surname><given-names>BW</given-names></name><name><surname>Arena</surname><given-names>R</given-names></name><name><surname>Biondi-Zoccai</surname><given-names>G</given-names></name><name><surname>Canada</surname><given-names>JM</given-names></name><name><surname>Oddi</surname><given-names>C</given-names></name><name><surname>Abouzaki</surname><given-names>NA</given-names></name><etal/></person-group>
<article-title>Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)</article-title>. <source>Am J Cardiol</source> (<year>2014</year>) <volume>113</volume>(<issue>2</issue>):<fpage>321</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.amjcard.2013.08.047</pub-id><?supplied-pmid 24262762?><pub-id pub-id-type="pmid">24262762</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavalli</surname><given-names>G</given-names></name><name><surname>Foppoli</surname><given-names>M</given-names></name><name><surname>Cabrini</surname><given-names>L</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Tresoldi</surname><given-names>M</given-names></name><name><surname>Dagna</surname><given-names>L</given-names></name></person-group>. <article-title>Interleukin-1 receptor blockade rescues myocarditis-associated end-stage heart failure</article-title>. <source>Front Immunol</source> (<year>2017</year>) <volume>8</volume>:<fpage>131</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2017.00131</pub-id><?supplied-pmid 28232838?><pub-id pub-id-type="pmid">28232838</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavalli</surname><given-names>G</given-names></name><name><surname>Pappalardo</surname><given-names>F</given-names></name><name><surname>Mangieri</surname><given-names>A</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Dagna</surname><given-names>L</given-names></name><name><surname>Tresoldi</surname><given-names>M</given-names></name></person-group>. <article-title>Treating life-threatening myocarditis by blocking interleukin-1</article-title>. <source>Crit Care Med</source> (<year>2016</year>) <volume>44</volume>(<issue>8</issue>):<fpage>e751</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1097/CCM.0000000000001654</pub-id><?supplied-pmid 27031379?><pub-id pub-id-type="pmid">27031379</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parisi</surname><given-names>F</given-names></name><name><surname>Paglionico</surname><given-names>A</given-names></name><name><surname>Varriano</surname><given-names>V</given-names></name><name><surname>Ferraccioli</surname><given-names>G</given-names></name><name><surname>Gremese</surname><given-names>E</given-names></name></person-group>. <article-title>Refractory adult-onset still disease complicated by macrophage activation syndrome and acute myocarditis: a case report treated with high doses (8mg/kg/d) of anakinra</article-title>. <source>Medicine (Baltimore)</source> (<year>2017</year>) <volume>96</volume>(<issue>24</issue>):<fpage>e6656</fpage>.<pub-id pub-id-type="doi">10.1097/MD.0000000000006656</pub-id><?supplied-pmid 28614216?><pub-id pub-id-type="pmid">28614216</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikonomidis</surname><given-names>I</given-names></name><name><surname>Lekakis</surname><given-names>JP</given-names></name><name><surname>Nikolaou</surname><given-names>M</given-names></name><name><surname>Paraskevaidis</surname><given-names>I</given-names></name><name><surname>Andreadou</surname><given-names>I</given-names></name><name><surname>Kaplanoglou</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis</article-title>. <source>Circulation</source> (<year>2008</year>) <volume>117</volume>(<issue>20</issue>):<fpage>2662</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.731877</pub-id><?supplied-pmid 18474811?><pub-id pub-id-type="pmid">18474811</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikonomidis</surname><given-names>I</given-names></name><name><surname>Tzortzis</surname><given-names>S</given-names></name><name><surname>Andreadou</surname><given-names>I</given-names></name><name><surname>Paraskevaidis</surname><given-names>I</given-names></name><name><surname>Katseli</surname><given-names>C</given-names></name><name><surname>Katsimbri</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis</article-title>. <source>Circ Cardiovasc Imaging</source> (<year>2014</year>) <volume>7</volume>(<issue>4</issue>):<fpage>619</fpage>&#8211;<lpage>28</lpage>.<pub-id pub-id-type="doi">10.1161/CIRCIMAGING.113.001193</pub-id><?supplied-pmid 24782115?><pub-id pub-id-type="pmid">24782115</pub-id></mixed-citation></ref></ref-list></back></article>